CN100406467C - Method for preparing total saponins from theroots of platycodon grandiflorum utilizing weak polarity macroreticular resin and its use - Google Patents
Method for preparing total saponins from theroots of platycodon grandiflorum utilizing weak polarity macroreticular resin and its use Download PDFInfo
- Publication number
- CN100406467C CN100406467C CNB2006100516078A CN200610051607A CN100406467C CN 100406467 C CN100406467 C CN 100406467C CN B2006100516078 A CNB2006100516078 A CN B2006100516078A CN 200610051607 A CN200610051607 A CN 200610051607A CN 100406467 C CN100406467 C CN 100406467C
- Authority
- CN
- China
- Prior art keywords
- total saponins
- balloonflower
- resin
- radix platycodi
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses a method for preparing extractions of total saponins of balloonflower by low-pole macroporous resin and purposes. Medicinal material of balloonflower is pulverized, or drinking pieces of balloonflower are directly used; water or 10% to 30% of ethyl alcohol is added, heating and refluxing extraction are carried out, extraction liquid is filtered and merged, and concentration is carried out; water is firstly used for washing resin by a chromatographic column filled with the low-pole macroporous resin after the filtering or centrifugation are carried out, and water eluent is discarded; ethyl alcohol containing water is used for eluting, and ethyl alcohol eluent is collected; the ethyl alcohol eluent is concentrated by reducing pressure, and the total saponins of balloonflower are obtained through pressure reduction or spray drying. The extractions of the total saponins of balloonflower containing the total saponins of balloonflower and balloonflower saponins D are used for preparing medicines of treating diabetes and resisting peripheral neuropathy, wherein the content of the total saponins of balloonflower is 50% to 90% of the weight of the extractions, and the content of the balloonflower saponins D is not below 1.0% of the weight of the extractions. The low-pole macroporous resin adopted in the present invention has large adsorption quantity to the total saponins of balloonflower, the total saponins of balloonflower are completely decomposed and adsorbed, and the content of the obtained total saponins is high. Thus, the present invention has the advantages that the extraction rate of the total saponins of knotted balloonflower can be obviously improved, and the production cost is reduced.
Description
Technical field
The present invention relates to a kind of method and purposes of utilizing the low-pole macroporous resin to prepare the Radix Platycodi total saponins extract.
Background technology
Balloonflower root (Radix platycodonis) is the dry root of campanulaceae Campanulaceae Platycodon grandiflouorum Platycodon grandiflorum.Its nature and flavor hardship, suffering, flat are returned lung channel, a surname's lung qi are arranged out, the effect of the apocenosis of eliminating the phlegm.Fitochemical studies is found, is mainly contained oleanolic acid type saponin component in the balloonflower root.Modern pharmacology test shows, balloonflower root has antibechic, eliminates the phlegm, anti-inflammatory, gastric acid inhibitory secretion and anti-gastric-ulcer, calmness, analgesic, reducing blood-fat, decreasing cholesterol, adjusting immunity of organisms, multiple pharmacological effect such as antibiotic and anticancer.
Macroporous adsorbent resin is meant that by vinylbenzene, alpha-methyl styrene, methyl methacrylate, propionitrile etc. for raw material adds the spherical particle that a certain amount of pore-creating agent divinylbenzene is polymerized, diameter is generally between 0.3-1.25mm.Now activeconstituents in the purifying natural plant is extracted in widespread use, as saponin(e, flavones, lactones, alkaloid etc.According to the macroporous resin chemical structure not with or have the surface properties of the functional group and the resin of opposed polarity, usually macroporous resin is divided into types such as nonpolar, low-pole and Semi-polarity.Wherein, the low-pole macroporous resin is the polymeric adsorbent that contains ester group, and its surface has hydrophobic and hydrophilic two portions concurrently, both can be by having adsorbed apolar substance in the polar solvent, again can be by adsorbing polar material in the non-polar solution, thereby range of application is more extensive.
Patent CN1566137A and patent CN1397560A openly utilize non-polar macroporous resin D101 and HPD-100 to produce the method for Radix Platycodi total saponins respectively, but do not have the concrete open wherein content of Radix Platycodi total saponins.Also there is the low shortcoming of content of the Radix Platycodi total saponins that the adsorptive capacity to Radix Platycodi total saponins is little, desorption efficiency is low and make in these two kinds of resins.
Summary of the invention
The purpose of this invention is to provide a kind of method and purposes of utilizing the low-pole macroporous resin to prepare the Radix Platycodi total saponins extract.
It is with the balloonflower root pulverizing medicinal materials or uses the balloonflower root medicine materical crude slice, adds 6～15 times of water gagings or 10%-30% ethanol, heating and refluxing extraction 2～4 times, and each 1～3h filters, and united extraction liquid is concentrated into 0.25～2.0g crude drug/ml; Filter or centrifugal back by being filled with the chromatography column of low-pole macroporous resin AB-8, extracting solution is 1: 5～10 by the ratio of Radix Platycodi total saponins content and dried resin, last column flow rate 1～4BV/h, resin path height ratio are 1: 3～1: 9; Wash resin 3～8BV with water, elution flow rate is 2-4BV/h, and water elution liquid discards; With 30～95% ethanol elutions, flow velocity is 2～4BV/h, collects ethanol eluate; It is 1.1～1.25 that ethanol eluate is evaporated to relative density, and decompression or spraying drying get Radix Platycodi total saponins.
Described centrifugal rotation speed is 4000～16000 rev/mins.The low-pole macroporous resin is a polystyrene type low-pole macroporous resin.
Utilize the low-pole macroporous resin to prepare the Radix Platycodi total saponins extract and be used to prepare the medicine for the treatment of diabetes, the medicine that is used to prepare anti-peripheral neuropathy.
The low-pole macroporous resin that the present invention adopts is big to the adsorptive capacity of Radix Platycodi total saponins, and complete by desorb, therefore the content height of gained total saponins, can significantly improve the extraction yield of Radix Platycodi total saponins, reduces production costs.
Embodiment
The present invention is directed to existing defective workmanship improves, utilize the low-pole macroporous resin to prepare the Radix Platycodi total saponins extract, Radix Platycodi total saponins content 50%-90% weight wherein, Platycodin D content is not less than 1.0% weight, compare by processing parameter with above-mentioned two kinds of resins, the result shows that the low-pole macroporous resin obviously is better than non-polar macroporous resin D101 and HPD100 to the adsorptive capacity of Radix Platycodi total saponins, and the content of the Radix Platycodi total saponins of desorption efficiency and acquisition is also apparently higher than the product that utilizes non-polar macroporous resin D101 and HPD100 to make.The present invention also provides the pharmacodynamics data of prepared Radix Platycodi total saponins extract for treating diabetic and analgesia, antithrombotic, anti-peripheral neuropathy simultaneously.
Prepared Radix Platycodi total saponins extract, Radix Platycodi total saponins content is not less than 50% weight (in Platycodin D), preferred 50%-90% weight, more preferably 50%-70% weight, this total saponins all has tangible reduction effect to the hyperglycemia that is caused by suprarenin, glucose, streptozotocin and tetraoxypyrimidine, has the effect of lowering blood glucose.Simultaneously, can significantly improve the rat nervus tibialis conductive impairment that causes by streptozotocin, improve motorial conduction of velocity (NCV), obviously shorten the refractory phase of Guo nest nerve.In addition, Radix Platycodi total saponins has stronger analgesic activity and platelet aggregation-against and antithrombotic effect.Can be used to prepare the medicine of treatment diabetes and analgesia, antithrombotic, anti-peripheral neuropathy.
The present invention can be used for preparing the purposes of the medicine of treatment diabetes and analgesia, antithrombotic, anti-peripheral neuropathy.The content that it is characterized in that Radix Platycodi total saponins is not less than 50% (Vanillin-Glacial acetic acid, perchloric acid colour developing, UV method, in Platycodin D, weight percent), and Platycodin D content is not less than 1.0% (HPLC method, weight percent).
Low-pole macroporous resin AB-8 and nonpolar D101, HPD100 type macroporous resin are to the comparison of Radix Platycodi total saponins adsorptive capacity, desorption efficiency and gained total saponin content:
Each 5 gram of resin, wash with water to there not being the alcohol flavor, decompressing and extracting, precision claims fixed, places the triangular flask of 250ml tool mill plug mouth, and each adds the sample liquid 150ml (being equivalent to the 45g crude drug) of preparation in early stage, 25 ℃ of constant temperature vibration 24h, get the soup of absorption front and back respectively, measure total saponin content, calculate resin than adsorptive capacity (mg/g dried resin).Than adsorptive capacity (mgg
-1Dried resin)=(total saponins amount before the absorption-absorption back total saponins amount)/resin dry weight.Resin with above-mentioned saturated absorption leaches respectively, with 30ml washing, blot surface-moisture after, add 70% ethanol 50ml desorb (25 ℃ of constant temperature jolting 24h), get measured in solution after the desorb, calculate the desorption efficiency of ethanol to each resin.Desorption efficiency=(total saponins amount/saturated extent of adsorption in the stripping liquid) * 100%.Stripping liquid is concentrated, drying under reduced pressure gets total saponins.Calculate the content of total saponins.Result such as table 1.
The dissimilar resins of table 1 are to the comparison of adsorptive capacity, desorption efficiency and the total saponin content of Radix Platycodi total saponins
The result shows that utilize low-pole macroporous resin AB-8 to prepare Radix Platycodi total saponins, not only adsorptive capacity is big, and the desorption efficiency height, products obtained therefrom content height.
The pharmacological action of Radix Platycodi total saponins
1. blood sugar reducing function
Under basic, normal, high dosage, Radix Platycodi total saponins all has tangible reduction effect to the hyperglycemia that is caused by suprarenin, glucose, streptozotocin and tetraoxypyrimidine, and dose-effect relationship is clear and definite.The animal euglycemia there is not obvious influence.
The medicine Radix Platycodi total saponins is self-control, and positive control is diabetes pill (Guangzhou Zhongyi Medicine Industry Co., Ltd); TANGMAIKANG JIAONANG (Zhonghui Pharmacy Co., Ltd., Chengdu).Urea assistant rhzomorph and tetraoxypyrimidine are Sigma company product.
The animal mouse, cleaning level, body weight 18g-22g, 50, male and female half and half are provided by the Academy of Medical Sciences, Zhejiang Experimental Animal Center, conformity certification number: SCXK (Zhejiang) 2003-0001.
Test-results
1.1 Radix Platycodi total saponins is to the influence of mouse euglycemia
Get 70 of healthy normal mouses, male and female half and half, be divided into 5 groups at random, be respectively blank group, model control group, diabetes pill group (2g/kg), three dosage groups of Radix Platycodi total saponins (40,20 and 10mg/kg), in 7 days every day gastric infusion once, irritate the long-pending 10ml/kg that is of body of stomach, fasting 12h before the last administration behind the administration 2h, measures blood sugar.
Table 2 Radix Platycodi total saponins is to the influence of mouse euglycemia (X ± S)
Annotate:
1*P＜0.05;
2*P＜0.01
3*P＜0.001
1.2 the influence of the mouse hyperglycemia that Radix Platycodi total saponins causes glucose
Get 60 of male and female half and half mouse, be divided into 5 groups at random, be respectively blank group, model control group, diabetes pill group by body weight, three dosage groups of Radix Platycodi total saponins (40,20 and 10mg/kg), in 7 days every day gastric infusion once, irritate the long-pending 10ml/kg that is of body of stomach, fasting 5h before the last administration, behind the last administration 1h, except that the blank group, all the other respectively organize equal abdominal injection glucose 2g/kg, 1h behind injectable dextrose monohydrate, with sacrifice of animal, get blood, measure blood sugar with blood glucose meter.The result shows: Radix Platycodi total saponins can obviously reduce the hyperglycemia that glucose causes.See Table 3.
Table 3 Radix Platycodi total saponins is to the influence of mouse hyperglycemia that glucose is caused (X ± S)
Annotate:
1*P＜0.05;
2*P＜0.01
3*P＜0.001
1.3 the influence of the mouse hyperglycemia that Radix Platycodi total saponins causes suprarenin
Grouping and administration experiment 1.2 together.After difference was last administration (non-fasting) 1h, except that the blank group, all the other respectively organized equal abdominal injection suprarenin 250 μ g/kg, and 1h behind the injection suprarenin with sacrifice of animal, gets blood, measures blood sugar.The result shows: Radix Platycodi total saponins can obviously reduce the hyperglycemia that suprarenin causes.See Table 4.
The influence of the mouse hyperglycemia that table 4 Radix Platycodi total saponins causes suprarenin (X ± S)
Annotate:
1*P＜0.05;
2*P＜0.01
3*P＜0.001
1.4 Radix Platycodi total saponins causes the influence of mouse hyperglycemia to streptozotocin
90 of male mices, get 10 at random as the blank group, all the other mouse tail vein injection streptozotocins (with the preparation of 0.05M citric acid pH4.5 body lotion, using immediately in the 4C ice bath) 200mg/kg causes diabetes model.Injection back 72h mouse socket of the eye vein is got blood and is surveyed blood sugar, deletion does not cause the diabetes model, and the person (surveys preceding fasting 12h, blood glucose value is lower than 11.11mmol/l), continue to employ mouse and be divided into 5 groups at random, every group 10, in 7 days, be administered once every day, not 2h after time administration by dosage shown in the table 3, the socket of the eye vein is got blood, surveys blood sugar with Ortho Toluidine method (ultramicromethod).The result shows: dosage group and high dose group cause that to streptozotocin the mouse hyperglycemia has tangible reduction effect, sees Table 5 in the Radix Platycodi total saponins.
Table 5 Radix Platycodi total saponins causes the influence (X ± S) of mouse hyperglycemia to streptozotocin
Annotate:
*P＜0.05;
*P＜0.01
1.5 Radix Platycodi total saponins causes the influence of mouse hyperglycemia to tetraoxypyrimidine
Grouping and administration experiment 1.2 together.After difference was last administration (non-fasting) 1h, except that the blank group, all the other respectively organized equal abdominal injection tetraoxypyrimidine, and dosage is 60mgkg
-1Behind about 1h, continue administration, continuous 3 days.Behind the last administration 1h, pluck the eyeball bloodletting, survey blood sugar.The results are shown in Table 6.
The total soap of table 6 balloonflower root causes the influence (X ± S) of mouse hyperglycemia to tetraoxypyrimidine
Annotate:
1*P＜0.05;
2*P＜0.01
3*P＜0.001
2. analgesic activity
Get 60 of mouse, be divided into 5 groups at random, gavage Radix Platycodi total saponins, the TANGMAIKANG KELI agent 0.2ml10g-1 of physiological saline, 3 dosage respectively, successive administration 7 days, last administration 1h, each treated animal abdominal injection 0.9% Glacial acetic acid 0.1ml10g
-1, mouse turns round the body number of times in the counting 20min.The results are shown in Table 7.
Table 7 Radix Platycodi total saponins Dichlorodiphenyl Acetate induced mice is turned round the influence of body number of times
Annotate:
1*P＜0.05;
2*P＜0.01
The result: Radix Platycodi total saponins has stronger analgesic activity.
3. Radix Platycodi total saponins is to the influence of external thrombus formation
Get 60 of mouse, be divided into 5 groups at random, gavage Radix Platycodi total saponins, the TANGMAIKANG KELI agent 1ml100g of physiological saline, 3 dosage respectively
-1Successive administration 10 days, behind the last administration 1h, animal is anaesthetized with vetanarcol, open the abdominal cavity, accurately get blood 2ml by not anti-freezing of Vena cava and place the plastic cement pipe rapidly, in the thrombosis instrument of preheating in advance, rotate 10min, afterwards removal of thromboses gently, on filter paper, blot watery blood, survey thrombus length, weight in wet base, again thrombus is placed 65 ℃ baking oven 30min, survey its dry weight.
The external antithrombotic of table 8 Radix Platycodi total saponins forms test-results
Annotate:
1*P＜0.05
The result: Radix Platycodi total saponins can significant platelet aggregation-against and anti-thrombosis function.
4. Radix Platycodi total saponins improves the rat nervus tibialis conductive impairment that caused by streptozotocin, improves motor nerve conduction velocity, obviously shortens the test of the refractory phase of Guo nest nerve
Get rat, be divided into 5 groups at random, behind the fasting 18h, prepare 2% streptozotocin solution with sodium citrate buffer, except that normal group, all the other each treated animals are abdominal injection 60mgkg respectively
-1Chain urea assistant bacterium, normal diet behind about 2h.Gavage physiological saline, Radix Platycodi total saponins (2 dosage), TANGMAIKANG KELI agent respectively, capacity is 1ml100mg
-1, every day 1 time, continuous 4 weeks.
4.1 neuroelectricity physical signs
ABR (brainstem auditory is brought out current potential): recording electrode (positive pole) places two trailing edge lines of rat center, indifferent electrode is connected to the homonymy ear-lobe, ground-electrode places the homonymy forelimb, TDH-39 type earphone is placed right ear canal, give the short sound of 80dB and stimulate guiding ABR, observe the peak latent period of main ripple, the stimulus intensity of decaying is then observed threshold value.
SEP (somatosensory evoked potential): stimulating electrode places left fore centre of the palm median nerve far-end.Recording electrode (negative pole) places that the mid point of offside eye socket trailing edge and auricle leading edge and head median line are other to be opened outside 1/2 the skull, and indifferent electrode (positive pole) places the offside ear-lobe.Bring out electro-induction with the sense of 3.0mA stimulus intensity guide body, survey peak latent period.
(4.2NCV motor nerve conduction velocity): stimulating electrode is put near the Guo nest nerve, recording electrode places the nervus peronaeus far-end, ground-electrode is connected to stimulating electrode and recording electrode line mid point, wherein the negative pole of stimulating electrode is towards the near-end of limbs, the negative pole of recording electrode is towards the far-end of limbs, amount stimulates the negative interpolar distance with recording electrode, then NCV=(distances between two negative poles of stimulating electrode and recording electrode)/peak latent period.
4.3 refractory phase: the same NCV of electrode position, with a day system SEN-3201 electrical stimulator, two pulse stimulates, and by regulating the timed interval of two pulse, observes motorial refractory phase reaction.
Table 9
Annotate:
2*P＜0.01
The result shows that Radix Platycodi total saponins can significantly improve the rat nervus tibialis conductive impairment that is caused by streptozotocin, improves motorial conduction of velocity (NCV), obviously shortens the refractory phase of Guo nest nerve.
Conclusion: this total saponins all has tangible reduction effect to have the effect of lowering blood glucose to the hyperglycemia that is caused by suprarenin, glucose, streptozotocin and tetraoxypyrimidine.Simultaneously, can significantly improve the rat nervus tibialis conductive impairment that causes by streptozotocin, improve motorial conduction of velocity (NCV), obviously shorten the refractory phase of Guo nest nerve.In addition, Radix Platycodi total saponins has stronger analgesic activity and platelet aggregation-against and antithrombotic effect.
Embodiment 1
Get the balloonflower root medicinal material 2kg after the pulverizing, add 6 times of water gagings, heating and refluxing extraction 2 times, each 1h filters, and united extraction liquid is concentrated into 0.25g crude drug/ml; Filter the back by AB-8 type macroporous resin, extracting solution is 1: 5 by the ratio of Radix Platycodi total saponins content and dried resin, and last column flow rate 1BV/h, resin path height ratio are 1: 3; Wash resin 3BV with water, elution flow rate is 2BV/h, and water elution liquid discards; With containing 30% aqueous ethanol wash-out 8BV, flow velocity is 2BV/h, collects ethanol eluate; It is 1.1 that ethanol eluate is evaporated to relative density, and drying under reduced pressure gets Radix Platycodi total saponins.Recording platycodin content is 50% (Vanillin-Glacial acetic acid, perchloric acid colour developing; The UV method; In Platycodin D, weight percent), Platycodin D content is 1.0% (HPLC method, weight percent).
Embodiment 2
With balloonflower root medicine materical crude slice 1kg, add 15 times of amount 30% ethanol, heating and refluxing extraction 4 times, each 3h filters, and united extraction liquid is concentrated into 2.0g crude drug/ml; Centrifugal back is by the chromatography column of AB-8 type macroporous resin, and extracting solution is 1: 10 by the ratio of Radix Platycodi total saponins content and dried resin, and last column flow rate 4BV/h, resin path height ratio are 1: 9; Wash resin 8BV with water, elution flow rate is 4BV/h, and water elution liquid discards; With containing 95% aqueous ethanol wash-out, flow velocity is 4BV/h, collects ethanol eluate; It is 1.25 that ethanol eluate is evaporated to relative density, and decompression or spraying drying get Radix Platycodi total saponins.Recording platycodin content is 77% (Vanillin-Glacial acetic acid, perchloric acid colour developing; The UV method; In Platycodin D, weight percent), Platycodin D content is 2.9% (HPLC method, weight percent).
Embodiment 3
Get the balloonflower root medicinal material 5kg after the pulverizing, add 8 times of water gagings, heating and refluxing extraction 2 times, each 1h filters, and united extraction liquid is concentrated into 1.0g crude drug/ml; Centrifugal (4000 rev/mins) back is by AB-8 type macroporous resin, and soup is 1: 5 by the ratio of Radix Platycodi total saponins content and dried resin, and last column flow rate 2BV/h, resin path height ratio are 1: 5; Wash resin 3BV with water, elution flow rate is 4BV/h, and water elution liquid discards; With containing 70% water-ethanol wash-out 3BV, flow velocity is 2BV/h, collects ethanol eluate; It is 1.1 (50 ℃ of heat are surveyed) that ethanol liquid is evaporated to relative density, and drying under reduced pressure gets Radix Platycodi total saponins.Recording platycodin content is 72% (Vanillin-Glacial acetic acid, perchloric acid colour developing; The UV method; In Platycodin D, weight percent), Platycodin D content is 2.1% (HPLC method, weight percent).
Embodiment 4
Balloonflower root pharmaceutical decocting piece 5kg adds 10 times of amount 10% ethanol, heating and refluxing extraction 2 times, and each 1.5h filters, and united extraction liquid is concentrated into 0.5g crude drug/ml; Filter the back by D201 type macroporous resin, soup is 1: 9 by the ratio of Radix Platycodi total saponins content and dried resin, and last column flow rate 3BV/h, resin path height ratio are 1: 7; Wash resin 5BV with water, elution flow rate is 4BV/h, and water elution liquid discards; With containing 30% water-ethanol wash-out 10BV, flow velocity is 4BV/h, collects ethanol eluate; It is 1.25 (50 ℃ of heat are surveyed) that ethanol liquid is evaporated to relative density, and spraying drying gets Radix Platycodi total saponins.Record platycodin content and be 66% (Vanillin-Glacial acetic acid, the perchloric acid colour developing, the UV method, in Platycodin D, weight percent), Platycodin D content is 1.1% (HPLC method, weight percent).
Embodiment 5
Balloonflower root pharmaceutical decocting piece 5kg adds 15 times of water gagings, heating and refluxing extraction 2 times, and each 1h filters, and united extraction liquid is concentrated into 0.25g crude drug/ml; Centrifugal (8000 rev/mins) back is by HPD450 macroporous resin, and soup is 1: 6 by the ratio of Radix Platycodi total saponins content and dried resin, and last column flow rate 4BV/h, resin path height ratio are 1: 9; Wash resin 2BV with water, elution flow rate is 3BV/h, and water elution liquid discards; With containing 50% water-ethanol wash-out 5BV, flow velocity is 3BV/h, collects ethanol eluate; It is 1.2 (50 ℃ of heat are surveyed) that ethanol liquid is evaporated to relative density, and spraying drying gets Radix Platycodi total saponins.Record platycodin content and be 70% (Vanillin-Glacial acetic acid, the perchloric acid colour developing, the UV method, in Platycodin D, weight percent), Platycodin D content is 2.2% (HPLC method, weight percent).
Claims (2)
1. method of utilizing the low-pole macroporous resin to prepare the Radix Platycodi total saponins extract, it is characterized in that: with balloonflower root pulverizing medicinal materials or balloonflower root medicine materical crude slice, add 6～15 times of water gagings or 10%-30% ethanol, heating and refluxing extraction 2～4 times, each 1～3h, filter, united extraction liquid is concentrated into 0.25～2.0g crude drug/ml; Filter or centrifugal back by being filled with the chromatography column of low-pole macroporous resin AB-8, extracting solution is 1: 5～10 by the ratio of Radix Platycodi total saponins content and dried resin, last column flow rate 1～4BV/h, resin path height ratio are 1: 3～1: 9; Wash resin 3～8BV with water, elution flow rate is 2-4BV/h, and water elution liquid discards; With 30%～95% ethanol elution, flow velocity is 2～4BV/h, collects ethanol eluate; It is 1.1～1.25 that ethanol eluate is evaporated to relative density, and decompression or spraying drying get Radix Platycodi total saponins.
2. a kind of method of utilizing the low-pole macroporous resin to prepare the Radix Platycodi total saponins extract according to claim 1 is characterized in that: described centrifugal rotation speed is 4000～16000 rev/mins.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100516078A CN100406467C (en) | 2006-05-24 | 2006-05-24 | Method for preparing total saponins from theroots of platycodon grandiflorum utilizing weak polarity macroreticular resin and its use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100516078A CN100406467C (en) | 2006-05-24 | 2006-05-24 | Method for preparing total saponins from theroots of platycodon grandiflorum utilizing weak polarity macroreticular resin and its use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1850851A CN1850851A (en) | 2006-10-25 |
| CN100406467C true CN100406467C (en) | 2008-07-30 |
Family
ID=37132353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100516078A Expired - Fee Related CN100406467C (en) | 2006-05-24 | 2006-05-24 | Method for preparing total saponins from theroots of platycodon grandiflorum utilizing weak polarity macroreticular resin and its use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100406467C (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101162710B1 (en) * | 2009-01-23 | 2012-07-05 | (주) 비엔씨바이오팜 | Pharmaceutical composition for preventing or treating Hepatitis C, comprising extract of Platycodon grandiflorum or Platycodon grandiflorum saponin compound |
| CN101904890A (en) * | 2009-06-02 | 2010-12-08 | 中国医学科学院药用植物研究所 | Preparation method, application and QC (Quality Control) detection method of platycodon grandiflorum active site |
| CN102423334B (en) * | 2011-09-30 | 2014-05-14 | 淮南联合大学 | Comprehensive extraction method for platycodin and platycodon grandiflorum polysaccharide |
| CN104817601B (en) * | 2015-03-31 | 2018-04-10 | 浙江大学 | Three flavones ingredient mixtures, preparation and its method are extracted from Herba lysimachiae capillipedis |
| CN111487349A (en) * | 2020-05-15 | 2020-08-04 | 易达斯生物科技(苏州)有限公司 | Chromatographic column for selective enrichment and purification of saponin and application method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1397560A (en) * | 2002-08-13 | 2003-02-19 | 吉林天药科技股份有限公司 | Process for extracting general platycodoside and platycoligenin D from platycodon root, its medical application and its Chinese medicine |
| CN1566137A (en) * | 2003-07-04 | 2005-01-19 | 深圳亿胜医药科技发展有限公司 | Production process for platycodin |
-
2006
- 2006-05-24 CN CNB2006100516078A patent/CN100406467C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1397560A (en) * | 2002-08-13 | 2003-02-19 | 吉林天药科技股份有限公司 | Process for extracting general platycodoside and platycoligenin D from platycodon root, its medical application and its Chinese medicine |
| CN1566137A (en) * | 2003-07-04 | 2005-01-19 | 深圳亿胜医药科技发展有限公司 | Production process for platycodin |
Non-Patent Citations (8)
| Title |
|---|
| 大孔吸附树脂在皂苷分离纯化中的应用. 徐先祥等.中国中医药信息杂志，第10卷第1期. 2003 |
| 大孔吸附树脂在皂苷分离纯化中的应用. 徐先祥等.中国中医药信息杂志，第10卷第1期. 2003 * |
| 大孔吸附树脂柱色谱法分离桔梗总皂苷. 杨献文等.吉林农业大学学报，第23卷第2期. 2001 |
| 大孔吸附树脂柱色谱法分离桔梗总皂苷. 杨献文等.吉林农业大学学报，第23卷第2期. 2001 * |
| 桔梗总皂甙制备工艺研究. 徐宝军，郑毅男.大连大学学报，第21卷第2期. 2000 |
| 桔梗总皂甙制备工艺研究. 徐宝军，郑毅男.大连大学学报，第21卷第2期. 2000 * |
| 电喷雾串联质谱法鉴定桔梗皂苷D1. 徐宝军等.中国药物化学杂志，第10卷第3期. 2000 |
| 电喷雾串联质谱法鉴定桔梗皂苷D1. 徐宝军等.中国药物化学杂志，第10卷第3期. 2000 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1850851A (en) | 2006-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2829275B1 (en) | Total flavone extract of abelmoschus manihot and preparation method thereof | |
| CN1883618B (en) | Effective parts of cirald daphne bark, preparation method and application thereof | |
| JP6091651B2 (en) | Pharmaceutical composition for treating headache and method for preparing the same | |
| CN104435226B (en) | Fevervine extract and application thereof | |
| CN100406467C (en) | Method for preparing total saponins from theroots of platycodon grandiflorum utilizing weak polarity macroreticular resin and its use | |
| CN112870236B (en) | Flavone effective part of abelmoschus manihot and preparation method and application thereof | |
| CN105920067A (en) | Sunflower calathide extract containing polysaccharide, flavonoid and alkaloid and preparation method of sunflower calathide extract | |
| CN101829214B (en) | Cherokee rose leaf extract and application thereof in preparing medicine capable of curing burn and scald | |
| CN104173453A (en) | Traditional Chinese medicinal composition used for preventing and treating infectious laryngotracheitis of chicken, and preparation method thereof | |
| CN107412430A (en) | A kind of radix scrophulariae water extract and its application | |
| CN109942491B (en) | Anti-inflammatory and analgesic C in monkshood20Diterpene alkaloid and application thereof | |
| CN102579559B (en) | Bauhinia championii ethyl acetate extract, n-butyl alcohol extract, and preparation methods and applications thereof | |
| CN102389496B (en) | Chinese medical composition for treating hepatitis and preparation method thereof | |
| CN105477126A (en) | Traditional Chinese medicine extract composition used for treating depression and preparation method and application thereof | |
| CN102293847B (en) | Chinese medicinal composition for treating constipation, acne and hyperlipidemia, and preparation method | |
| CN107412462B (en) | Preparation method of Huanglong cough and asthma capsule | |
| CN101147767B (en) | Preparation method of medicinal composition for treating acne | |
| CN102949681B (en) | Composition for preventing or treating colds, and its preparation method | |
| CN102716231B (en) | A kind of Chinese medicine composition and application thereof for the treatment of brain injury and cerebral edema | |
| CN102579558B (en) | Application of bauhinia championii total flavonoids in preparation of medicine for treating rheumatoid arthritis | |
| CN110092806B (en) | Analgesic C of aconite19Diterpene alkaloid glucoside and application thereof | |
| CN101564418B (en) | Pharmaceutical composition for treating oral ulcer | |
| CN112279811A (en) | C20Diterpenoid alkaloids, their preparation and use for treating pain related diseases | |
| KR20190102846A (en) | Novel use of xanthii fructus extract for preventing or treating sleep disorders | |
| CN102351874B (en) | New erigeroster compound with medicinal activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080730 Termination date: 20130524 |